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ENGLISH SUMMARY 
 
Background 
Although great progress has been made in defining genes conferring the majority of genetic risk in 
Long QT Syndrome (LQTS) patients, there remains a substantial challenge to explain the widely 
observed variability in disease expression and phenotype severity, even among family members, 
sharing the same mutation. Identifying clinical and genetic variables capable of 
influencing/predicting the clinical phenotype of LQTS patients would allow a more accurate risk 
stratification, important for determining prognosis, selecting patients for the most appropriate 
therapy, and counseling asymptomatic mutation carriers (MCs). 
To address these questions an Italian LQT2 family and a South African Founder LQT1 population 
have been used. 
Methods and Results 
Italian LQT2 family. The proband, a 44-yr-old white woman, presented with ventricular fibrillation 
and cardiac arrest. Intermittent QT prolongation was subsequently observed and LQT2 was 
diagnosed following the identification of a missense KCNH2 mutation (A1116V). The proband also 
carried the common KCNH2 polymorphism K897T on the non-mutant allele. Relatives who carried 
A1116V without K897T were asymptomatic but some exhibited transient mild QTc prolongation 
suggesting latent disease. Expression studies in Chinese Hamster Ovary (CHO) cells, demonstrated 
that the presence of KCNH2-K897T is predicted to exaggerate the IKr reduction caused by the 
A1116V mutation. These data explain why symptomatic LQTS occurred only in the proband 
carrying both alleles. 
South African LQT1 population. The study population involved 320 subjects, 166 MCs and 154 non 
mutation carriers (NMCs). Off ß-blocker therapy, MCs had a wide range of QTc values (406-676 
ms) and a QTc>500 ms was associated with increased risk for cardiac events (OR=4.22; 95%CI 
1.12-15.80; p=0.033). We also found that MCs with a heart rate <73 bpm were at significantly 
lower risk (OR=0.23; 95%CI 0.06-0.86; p=0.035). In a subgroup of patients Baroreflex Sensitivity 
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(BRS) was determined both in presence and absence of ß-blocker therapy. BRS, analyzed in 
subjects in the 2nd and 3rd age quartiles (age 26-47) to avoid the influence of age, was lower among 
asymptomatic than symptomatic MCs (11.8±3.5 vs 20.1±10.9 ms/mmHg, p<0.05). A BRS in the 
lower tertile carried a lower risk of cardiac events (OR 0.13, 95%CI 0.02-0.96; p<0.05). This study 
also unexpectedly determined that KCNQ1-A341V was associated with greater risk than that 
reported for large databases of LQT1 patients: A341V MCs were more symptomatic by age 40 
(79% vs 30%) and became symptomatic earlier (7±4 vs 13±9 years), both p<0.001. Accordingly, 
functional studies of KCNQ1-A341V in CHO cells with KCNE1, identified a dominant negative 
effect of the mutation on wild-type channels. 
Conclusion 
Our findings indicate that risk stratification for LQTS patients must be more individually tailored 
and may have to take into account the specific mutation and probably additional clinical and genetic 
variables capable of influencing/predicting the clinical phenotype of LQTS patients. As a matter of 
fact, we have provided evidence that a common KCNH2 polymorphism may modify the clinical 
expression of a latent LQT2 mutation and the availability of an extended kindred with a common 
mutation allowed us to highlight that KCNQ1-A341V is associated with an unusually severe 
clinical phenotype and to identify two autonomic markers, HR and BRS, as novel risk factors. 
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AFRIKAANSE OPSOMMING  
Agtergrond 
Alhoewel groot vooruitgang gemaak is in herkenning van die bydrae wat enkelgene maak tot risiko 
in pasiënte met die Lang QT Sindroom (LQTS), is `n beduidende uitdaging om die waargenome 
veranderlikheid in siekte-uitdrukking en graad van aantasting, selfs onder lede van dieselfde familie 
wat dieselfde mutasie deel, te verklaar.  Die  identifikasie  van kliniese en genetiese veranderlikes 
wat die vermoë het om die  die kliniese fenotipe van pasiënt met LQTS te beïnvloed/voorspel sal ‘n 
meer akkurate risiko stratifikasie toelaat.  Hierdie is belangrik vir die bepaling van prognose, keuse 
van pasiënte vir die beste toepaslike behandeling, en berading van asimptomatiese mutasiedraers 
(MCs).  Om die vrae aan te spreek is ‘n Italiaanse LQT2 familie en ‘n Suid-Afrikaanse 
stigtersbevolking gebruik. 
Metodes en Resultate 
Italiaanse LQT2 familie. Die indeksgeval is ‘n 44 jaar-oue wit vrou wie met ventrikulêre fibrillasie 
en hartstilstand voorgedoen het. Intermitterende QT verlenging is later waargeneem (maksimum 
QTc 530 ms.) en LQT2 word diagnoseer na identifikasie  van ‘n KCNH2 mutasie (A1116V).  Die 
indeksgeval dra ook ‘n algemene KCNH2 polimorfisme K897T op die nie-mutant allel. Familielede 
wat die A1116V sonder K897T dra was nie simptomaties nie, maar sommige vertoon voorbygaande 
geringe verlenging van QTc wat latente siekte suggereer. Geenuitdrukkingstudies wat in Chinese 
hamster ovariële (CHO) selle  uitgevoer is, demonstreer dat die teenwoordigheid van KCNH2-
K897T voorspel dat ‘n vergrote IKr afname sal plaasvind as gevolg van die A1116V mutasie. 
Hierdie gegewens verklaar waarom simptomatiese LQTS slegs in die indeksgeval, wie beide allele 
dra, voorkom. 
Suid-Afrikaanse LQT1 stigterbevolking. Die studiepopulasie het 320 persone betrek, 166 
mutasiedraers (MCs) en 154 nie-mutasiedraers (NMCs). Van ß-blokker behandeling af het MCs ‘n 
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wye strek van QTc waardes (406-676ms) en 12% van individue had ‘n normale QTc (≤. 440ms). ‘n 
QTc >500 was assosieerd met ‘n verhoogde risiko vir hartverwante gebeurtenisse (OR=4.22; 
95%CI 1.12-15.80; p=0.033). Ons het ook bevind dat MCs met ‘n hartspoed  <73 slae per minuut ‘n 
beduidende laer risiko gehad het (OR=0.23; 95%CI 0.06-0.86; p=0.035).  In ‘n subgroep van 
pasiënte is baroreseptorsensitiwiteit (BRS) bepaal beide in die teenwoordigheid en in die 
afwesigheid van ß-blokker behandeling. BRS, soos ontleed in studiepersone in die 2de and 3de 
ouderdomskwartiele om die invloed van ouderdom te vermy, was laer onder asimptomatiese dan 
simptomatiese MCs (11.8±3.5 vs 20.1±10.9 ms/mmHg, p<0.05). ‘n BRS in die laer tertiel had ‘n 
laer risiko van kardiale gebeurtenisse gehad (OR 0.13, 95%CI 0.02-0.96; p<0.05). Die studie het 
ook onverwags gevind dat KCNQ1-A341V ‘n groter risiko het dan die wat rapporteer is vir groot 
databasisse van LQT1 pasiënte: A341V MCs meer simptomaties by ouderdom 40 (79% versus 
30%) en word vroeër simptomaties (7± 4 jare gevind versus 13±9), beide p<0.001. 
Diensooreenkomstig, is die funkionele studies van KCNQ1-A341V in CHO selle met KCNE1 
uitgevoer en word ‘n dominant-negatiewe ten opsigte van die mutasie op wilde-tipe kanale 
demonstreer. 
Gevolgtrekking 
Ons bevindings wys daarop dat die risikostratifiaksie van pasiënte met LQTS meer individu-
spesifiek gemaak moet word en dat mens moontlik die spesifieke mutasie en waarskynlik ekstra 
kliniese en genetiese veranderklikes in berekening moet bring om die klniese  fenotipe te voorspel. 
In werklikheid, het ons bewys gelewer dat ‘n algemene polimorfisme KCNH2 kliniese  uitdrukking 
van latente LQT2 kan wysig. Verder het die beskikbaarheid van ‘n uitgebreide familieboom wat  ‘n  
mutasie deel ons toegelaat om aan te toon dat KCNQ1-A341V met ‘n ongewoon erge kliniese 
fenotipe assosieer is en om twee autonome merkers, hartspoed en BRS, as voorheen nie-beskrewe  
risikofakore, te identifiseer. 
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NOTES: 
Part of the data presented in this thesis have been published in two different articles: 
1. Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, Vicentini A, 
Yang P, Roden DM, George AL Jr, Schwartz PJ. A common HERG polymorphism, K897T, 
acts as a genetic modifier of the Congenital Long QT Syndrome. Circulation 2005; 
112:1251-1258. 
2. Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, Heradien M, 
Geldenhuys G, Vanoli E, Bacchini S, Spazzolini C, Lundquist AL, Roden DM, George AL, 
Schwartz PJ. Phenotipic variability and unusual clinical severity of congenital Long QT 
Syndrome in a Founder Population. Circulation 2005; 112: 2602-2610.  
 
Candidate’s personal involvement in the different experiments reported: 
 
Clinical Phenotyping:  
• I have personally collected all the clinical information of the Italian LQTS family, that I am 
currently following in the “Molecular Cardiology Ambulatory” in the University Hospital 
“Policlinico San Matteo”  in Pavia,  under the direction of Prof. Peter Schwartz.  
• I have actively participated in the collection of all the clinical and autonomic data of the 
South African families together with Prof. Paul Brink, Prof. Emilio Vanoli and Ms Althea 
Goosen, sometime with the participation of additional South African or Italian personnel.  
• I also created a database in Filemaker Pro and with the help of Ms Althea Goosen all the 
clinical paper-files of the South African patients, written in Afrikaans, were converted in 
electronic files written in English and were enriched with the clinical information collected 
during the visit of a number of these patients. This database was the starting point for most 
of the analyses that we have performed and that we are currently performing. To perform 
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this part of the project I went to Cape Town three times a year (for three weeks each time) 
for a period of 4 years. 
• Molecular investigation: I have personally performed the molecular screening of our 
Italian Family in the “Molecular Cardiology Laboratories”, in the University Hospital 
“Policlinico San Matteo” in Pavia,  under the direction of Prof. Peter Schwartz. Nowadays 
there are three molecular biologists working in the laboratory; therefore I don’t do the work 
personally anymore, but the work I describe in this thesis was performed by myself. The 
Haplotype work on the South Africa families was performed by the South African group 
under the direction of Prof. Valerie Corfield and Prof. Paul Brink. 
• Functional Study: the biophysical characterization of the KCNH2 variants and of the 
KCNQ1-A341V variant was performed in the Department of Genetic Medicine at the 
University of Vanderbilt, Nashville, Tennessee (USA), under the direction of Prof. Alfred L. 
George. I spent three months working in his laboratories and I personally performed site-
directed mutagenesis and cloning both the wild-type and the mutant alleles into pIRES-
EGFP and pIRES-DsRed for use in co-expression study. I also transfected the plasmid DNA 
in CHO cells. The patch clamp work, was performed by Mr. Andrew Lundquist, under Prof. 
Alfred L. George supervision. 
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ABBREVIATIONS LIST 
 
BB            ß-blocker   
BRS         Baroreflex sensitivity 
CHO        Chinese Hamster Ovary cells  
CI             Confidence Interval  
ECG         Electrocardiogram 
EGFP        Enhanced Green Fluorescent Protein 
HR            Heart Rate 
ICD           Internal Cardioverter Defibrillator  
IQR           Interquartile Range 
IRES         Internal Ribosomal Entry Site 
IT              Italian 
LQTS       Long QT Syndrome 
LQT1       Long QT Syndrome type 1 (disease-causing mutation on KCNQ1) 
LQT2       Long QT Syndrome  type 2 (disease-causing mutation on KCNH2) 
MCs         Mutation Carriers 
NMCs      Non Mutation Carriers 
OR           Odd Ratio 
PCR         Polymerase Chain Reaction 
Pts            Patients 
QTc          QT corrected for heart rate by using Bazett’s formula 
SA            South African 
SD            Standard Deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ix
INDEX 
Declaration                  Page ii 
English summary                  Page iii 
Afrikaans summary                  Page v 
Notes                                                                                                                      Page vii 
Abbreviations list                  Page ix 
Introduction                                                                                                           Page 1 
Methods                                                                                                                  Page 5 
        Study Populations                                                                                          Page 5 
        Genotyping/Haplotyping                                                                               Page 6 
        Phenotypic Assessment                                                                                  Page 7 
        Statistical Analysis                                                                                          Page 9 
        Site-Directed Mutagenesis                                                                             Page 10 
        Cell Culture and Electrophysiology                                                              Page 11 
Results: Italian LQT2 Family (IT-A1116V)                                                         Page 14 
         Clinical Phenotype                                                                                        Page 14 
          Identification of a novel KCNH2 mutation                                                Page 14 
         Segregation of KCNH2 variants                                                                  Page 15 
         Biophysical characterization of KCNH2 variants                                     Page 16 
Results: South African LQT1 Founder Population (SA-A341V)                       Page 25 
         Family Ascertainment, Genealogy, and Genotyping                                Page 25 
         Clinical Phenotypes                                                                                      Page 25 
         Baroreflex Sensitivity and Risk for Cardiac Events                                 Page 27 
         Clinical Severity in the South African LQTS Population                         Page 28 
         Functional characterization of KCNQ1-A341V                                         Page 30 
Discussion: Italian LQT2 Family (IT-A1116V)                                                    Page 44 
 x
          Genetic Modifiers of LQTS                                                                         Page 44 
          Clinical and Functional Significance of KCNH2-K897T                          Page 46 
          Implications for Risk Stratification in LQTS                                            Page 48 
 
Discussion: South African LQT1 Founder Population (SA-A341V)                   Page 49 
          Phenotypic Heterogeneity in a LQTS Founder Population                      Page 49 
          Heart Rate as a Risk Factor in LQTS                                                         Page 50 
          Lower Baroreflex sensitivity correlates with reduced arrhythmia risk   Page 52 
          Clinical Severity in SA-A341V                                                                     Page 53 
          Dominant Suppression of IKs by KCNQ1-A341V                                       Page 54 
Conclusions and clinical implications                                                                    Page 56 
References                                                                                                                Page 57 
 
 
 
 
          
 
           
 
 
 
 
 
  
          
 
 xi
 
 
LIST OF FIGURES 
 
 
Figure 1: ECG recordings from the IT-A1116V proband.                                          Page 18 
Figure 2: Hyperventilation test in the IT-A1116V proband.                                       Page 19 
Figure 3: Identificaton of KCNH2-A1116V.                                                               Page 20 
Figure 4: Segregation of A1116V and K897T in the LQTS pedigree.                        Page 21 
Figure 5: Characterization of asymptomatic KCNH2-A1116V carriers.                     Page 22 
Figure 6: Functional characterization of A1116V and K897T HERG variants.          Page 23 
Figure 7: Coexpression of HERG variants.                                                                  Page 24 
Figure 8: Lines of descent of the KCNQ1-A341V mutation from a founder couple.   Page 31 
Figure 9: Flow-chart with the number of subjects, divided by subgroups.                   Page 32 
Figure 10: Basal QTc in mutation and non-mutation carriers.                                      Page 33 
Figure 11: Basal QTc in symptomatic and asymptomatic mutation carriers.                Page 34 
Figure 12:  Distribution of MCs according to symptoms, HR and QTc.                       Page 35 
Figure 13:  Percentage of symptomatic pts with QTc <500 ms in each tertile of HR    Page 36 
Figure 14:  BRS values in different subgroups.                                                              Page 37 
Figure 15:  Distribution of MCs according to symptoms, BRS and QTc.                      Page 38 
Figure 16: Effect of BB on BRS.                                                                                     Page 39 
Figure17: Kaplan-Meier curves of event free survival in the entire SA population.       Page 40 
Figure 18: Kaplan-Meier curves  among females with a QTc ≥ 500 msec.                     Page 41 
Figure 19: Comparison between SA-A341V and LQT1 reported by Zareba.                 Page 42 
Figure 20: Functional characterization of KCNQ1-A341V.                                           Page 43 
 
 
 
 
 xii
 xiii
ACKNOWLEDGENTS 
 
I would like to thank Prof. Paul A. Brink for giving me the opportunity of being part 
of the University of Stellenbosch and of getting a PhD from this University. I feel this 
is a great honour. I would also like to thank Prof. Paul A. Brink along with Ms Althea 
Goosen, Prof Valerie Corfield, Ms Paula Hedley, Ms Glenda Durrheim and Dr. 
Marshall Heradien for having worked with me and with people in my own group with 
such a high enthusiasm and team-effort drive. I will never forget the months spent in 
South Africa that have enriched me not only from the professional point of view, but 
greatly from a personal point of view. I had the opportunity to meet wonderful people 
and to understand better the history of a Nation that has so much to teach in its 
transition from Apartheid to Democracy.  
I thank Prof. Peter J. Schwartz for giving me the opportunity of being part of this 
exciting research project and Prof. Emilio Vanoli for sharing with me this great 
experience with his joy and enthusiasm for life.   
I thank Prof. Alfred L. George for his friendship and for his fundamental working 
support.  
I thank Ambrogio for giving me his continuous support and encouragement 
throughout this project, even if my working passion was keeping me far away from 
him for so long. 
I thank my parents, Tecla and Guido, for their support and for believing in my dreams 
to be a physician first, then a cardiologist and now a doctor in Philosophy.  
I thank my new family, my old family and all my friends and relatives for having 
enriched my life with their love.   
 
 
 1
 
INTRODUCTION 
 
The congenital long QT syndrome (LQTS) is an inherited disorder characterized by 
prolongation of the QT interval and an increased risk for life-threatening ventricular arrhythmias 
(1,2). The disease is genetically heterogeneous caused by mutations in one of several genes 
including KCNQ1, KCNH2, KCNE1 and KCNE2 encoding potassium channel subunits, the cardiac 
sodium channel gene SCN5A, the L-type calcium channel gene CACNA1C (3,4), CAV3 and SCNB4 
(5,6).  
There are several reasons for the current widespread interest in LQTS. One is represented by 
the dramatic manifestations of the disease, namely syncopal episodes which often result in cardiac 
arrest and sudden death and usually occur in conditions of either physical or emotional stress in 
otherwise healthy young individuals, mostly children and teenagers. Another reason is that, while 
LQTS is a disease with a very high mortality rate among untreated patients, very effective therapies 
are available; this makes the existence of symptomatic and undiagnosed or misdiagnosed patients 
unacceptable and inexcusable. Finally, the identification of genes associated with the congenital 
long QT syndrome (LQTS) has had a major impact on understanding the molecular basis for 
ventricular arrhythmias and sudden cardiac deathP P(7). The impressive correlation between specific 
mutations and critical alterations in the ionic control of ventricular repolarization makes this 
syndrome a unique paradigm which allows to correlate genotype and phenotype, thus providing a 
direct bridge between molecular biology and clinical cardiology in the area of sudden cardiac death. 
Although great progress has been made in defining individual genes conferring the majority 
of genetic risk in LQTS patients and in elucidating complex genotype-phenotype correlations (8-
10), there remains a substantial challenge to explain the widely observed variability in disease 
expression and phenotype severity. As a matter of fact, members of the same family that share the 
same mutation may have varying degrees of QT prolongation and widely different phenotypes, 
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ranging from no symptoms to sudden death and the underlying mechanisms of this phenotypic 
variability are still unknown.  Identifying clinical and genetic variables capable of 
influencing/predicting the clinical phenotype of LQTS patients would allow a more accurate 
risk stratification, important for determining prognosis, selecting patients for the most 
appropriate therapy, and counseling asymptomatic mutation carriers (MCs).  
The main objective of this study is to test our hypothesis (11) that, among LQTS patients, 
clinical severity is modified – in addition to already known factors such as gender and QT interval 
duration – by the autonomic nervous system and by genetic variants that could contribute to a 
greater or lesser propensity to respond to stimuli with release of catecholamines and/or by variants 
on the genes causing LQTS that might increase the loss of repolarizing potassium currents and 
further prolong the QT interval in some patients, thereby further increasing their risk for cardiac 
events. In the present study we will focus on the two main genetic subgroups, LQT1 and LQT2, 
which together account for 90% all LQTS. 
We have previously shown (12) that most cardiac events (96%) in the LQT1 subgroup are 
triggered by either physical exercise (68%) or by emotional stress (28%). Both of these conditions 
involve a rapid or sudden increase in catecholamines release. The underlying predisposing 
mechanism is represented by a reduction in IBKs B current, the hallmark of the LQT1 subgroup. The 
LQT2 subgroup has a unique position because even though the normal IBKs B current prevents events 
during exercise, these patients are exquisitely sensitive to startle, especially auditory stimuli as a 
telephone ring or an alarm clock (12). For these patients the most dangerous trigger is represented 
by an unexpected startle while at rest; hence, another specific relation with sudden release of 
norepinephrine. Thus, it is especially in the LQT1 subgroup – but also, in a different way, in the 
LQT2 subgroup - in which variability in sympathetic activation or in its effects on the ventricular 
myocytes is more likely to determine outcome, that one can expect genetic alterations or 
abnormalities in the sympathetic control of cardiac function to play a "modifier" role on the clinical 
expression of LQTS. These considerations provide the rationale for the exploration of the 
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"adrenergic cascade", upstream and downstream, to assess the presence of functional 
polymorphisms that might modify either the amount of norepinephrine (and/or of epinephrine) 
released at the ventricular level or the sensitivity of the adrenergic receptors to catecholamines.  
Experimental (13) and clinical studies (14) carried out by our group have shown that, in the 
presence of an arrhythmogenic substrate such as a healed myocardial infarction, a major risk factor 
for sudden arrhythmic death is represented by "autonomic imbalance". This term indicates an 
alteration in the balance between sympathetic and vagal activity, such as an increase of sympathetic 
and/or decrease in vagal activity. The latter is often the primary determinant of this arrhythmogenic 
imbalance that is identified clinically by a reduction in Baroreflex Sensitivity (BRS), a marker of 
the ability to reflexly increase vagal activity [ a factor that, by antagonizing sympathetic activity, 
has a protective action against ventricular fibrillation (14) ]. There is growing evidence that BRS 
has a wide distribution in normal individuals (13-15) and that it is genetically determined to a strong 
degree (16-17). The direct link with the present project is represented by the fact that genetic 
alterations leading to a lower-than-normal BRS will result in more norepinephrine being released 
under stress. Individuals genetically predisposed toward lower values of BRS will respond to 
physical or emotional stress with more NE acting on the heart, partly because of reduced vagal 
antagonism. If they have an arrhythmogenic substrate, myocardial infarction UorU LQTS, they will be 
at higher risk for life-threatening arrhythmias. This is what we have already demonstrated for 
myocardial infarction (14) and what we will test in the present study.   
Thus, as recently proposed (11 ), in the search for genes that modify the propensity for life-
threatening arrhythmias, there is a strong rationale to screen LQT1 and LQT2 patients for 
polymorphisms which might affect sympathetic function, baroreflex sensitivity or the degree of 
potassium channels activation during sympathetic activation. Also the duration of the QT interval is 
an important risk stratifier (8). As polymorphisms on the genes known to cause LQTS could further 
affect QT duration, this is an additional area worth exploring.  
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To address these questions an Italian LQT2 family and a South African Founder LQT1 
population have been used, providing new genetic and clinical insights into the comprehension of 
disease-expression variability.   
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METHODS 
Study Populations 
Italian LQT2 Family (IT-A1116V) 
 A 44-year old white Italian female presented to IRCCS Policlinico San Matteo for clinical 
care following cardiac arrest due to ventricular fibrillation. After informed consent was obtained 
using a protocol approved by the Ethics Review Board of the Policlinico San Matteo, Pavia, blood 
was collected from the proband and members of her extended family for isolation of DNA. The 
proband and the family members were evaluated with basal electrocardiogram (ECG), 
hyperventilation test, exercise stress test, echocardiogram and 12-lead ECG 24 hour Holter 
Recording. Clinical and genetic data were recorded on specific forms and included demographic 
information, personal and family history of disease, symptoms and therapy. Data were subsequently 
stored in the database of the “Cardiac Arrhythmogenic Diseases Outpatient Clinic” of the 
Policlinico San Matteo, Pavia.  
South African LQT1 Founder Population (SA-A341V) 
A cohort of individualsP P(18) harboring an identical LQTS-causative mutation in KCNQ1 
(A341V) was investigated for the possibility of a founder effect. Starting from probands, family 
trees were constructed and ancestral relationships were researched through genealogical studies. To 
exclude the possibility that the mutation arose independently on more than one occasion, which 
would be contrary to the founder hypothesis, haplotype data on the genomic segment encompassing 
KCNQ1 were also used to confirm likely lines of descent of the shared A341V mutation from the 
founding couple. 
Clinical and genetic data concerning mutation-carriers (MCs) and first degree relatives were 
recorded on designed forms and included demographic information, personal and family history of 
disease, symptoms and therapy. Cardiac events were defined as syncope (fainting spells with 
transient, but complete, loss of consciousness), aborted cardiac arrest (requiring resuscitation) and 
sudden cardiac death. Mutation carriers were classified as either symptomatic or asymptomatic. 
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Symptomatic patients were MCs who experienced at least one episode of syncope or cardiac arrest, 
whereas asymptomatic MCs were those individuals without these events. Unexpected sudden death 
that occurred before age 40 without a known cause was categorized as related to LQTSP P(19) and 
was assumed to have occurred in MCs. Data were stored in a relational database developed jointly 
by authors from the University of Stellenbosch and from the University of Pavia. 
All probands and family members provided written informed consent for clinical and 
genetic evaluations. Protocols were approved by the Ethical Review Boards of the Tygerberg 
Hospital of Stellenbosch University, Vanderbilt University, and the University of Pavia. Approved 
consent forms were provided in English or Afrikaans as appropriate. 
 
Genotyping/Haplotyping 
Italian LQT2 Family (IT-A1116V) 
Genomic DNA was extracted from peripheral blood leukocytes using standard methods and 
diluted to 50ng/µl. All coding exons of KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2 were 
amplified by polymerase chain reaction (PCR) using previously published primer pairs (20-24) or 
additional primers with annealing temperatures of 53-69 °C. Amplicons were screened for sequence 
variants using denaturing high performance liquid chromatography (DHPLC) analysis performed on 
two different automated DNA fragment analysis systems (WaveTM models 1100 and 3500HT, 
Transgenomic, San Jose, CA). Elution profiles were compared with normal control samples 
included in each analysis. Products exhibiting divergent chromatographic profiles were 
enzymatically purified (ExoSAP-IT; Amersham Bioscience, Piscataway, NJ, USA) and sequenced 
(Big-Dye Terminator v1.1 cycle sequencing kit; Applied Biosystems) with an ABI Prism 310 
Genetic Analyzer (Applied Biosystems, Foster City, CA). 
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South African LQT1 Founder Population (SA-A341V) 
Peripheral blood was collected from all index cases and family members entered into the 
study. Genomic DNA was extracted from lymphocytes or Epstein-Barr virus-transformed cell lines 
as previously describedP P(25). 
 Polymerase chain reaction (PCR)-based detection of the A341V founder mutation, which 
results in the loss of a HhaI restriction enzyme site in KCNQ1 exon 7, was used to genotype 
members of the LQTS families. Exon 7 was PCR amplified, by using primers X7F and X7RP P(26) to 
generate a 190 bp amplicon for restriction digestion. 
Selected informative members of each LQTS-affected family were genotyped at eight linked 
microsatellite loci (D11S4046, D11S1318, D11S4088, D11S4146, D11S4181, D11S1871, 
D11S1760, D11S1323) that span the KCNQ1 region. Haplotypes were determined by studying 
family structures and by using Mendelian rules of inheritance. 
 
Phenotypic Assessment 
Italian LQT2 Family (IT-A1116V) 
 Baseline ECG, hyperventilation test, exercise stress test, echocardiogram and 12-lead ECG 
24 hours Holter Recording were performed in the proband and in her family members. Duration of 
the QT and RR intervals in leads II and V3 were measured from the different ECGs available. To 
allow QT values to be compared among subjects, the QT interval was corrected for heart rate (QTc) 
by using Bazett’s formula 
South African LQT1 Founder Population (SA-A341V) 
A baseline ECG recorded in the absence of β-blocker therapy was available for 131/154 
(85%) non-carriers and for 93/166 (56%) MCs. All ECGs were coded and the most recent one not 
on therapy was subsequently analyzed blinded to genotype.  
Baseline heart rate (HR) and duration of the QT and RR intervals in leads II and V3 were 
measured from resting 12-lead ECGs. To allow QT values to be compared among subjects, the QT 
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interval was corrected for heart rate (QTc) by using Bazett’s formula. For comparisons of heart rate 
and QTc between symptomatic and asymptomatic patients, we used only ECGs recorded after age 
15. This was done because the heart rate of healthy individuals is significantly greater before age 15 P 
P(27) and because absence of cardiac events before age 15 does not predict that an LQTS proband 
will remain asymptomatic throughout life. Thus,  7 patients with an ECG taken before age 15 were 
not included in this analysis, which therefore is limited to 86 patients. 
Eighty-three subjects accepted to perform an “Autonomic Evaluation Study”. Accordingly, 
all subjects were either hospitalized or stayed in a hotel close to Tygerberg Hospital for 4 days to 
perform the study both on and off beta-blocker therapy. Plasma concentrations of propranolol and 
atenolol were determined by a sensitive and specific method using high-performance liquid 
chromatography (HPLC) with fluorometric detection, modified by Braza AJ et al (28). Plasma 
levels below 20 ng/mL were considered as “non therapeutic”. 
After environmental acclimation, while the subjects were resting comfortably, ECG, blood 
pressure, and respiratory activity were simultaneously recorded for a 10-minute period, digitized 
and stored by a PC based software system (Bioengineering Service Montescano, Italy). BRS was 
determined (at least two determinations per subject) by the phenylephrine method, relating a 
transient increase in blood pressure (20-30 mmHg) induced by bolus injections of phenylephrine (2-
3 μg/kg, as necessary) to the resultant lengthening of the RR interval (29). The slope of a best-fit 
regression line defined BRS. Beat-to-beat RR interval and blood pressure (BP) were continuously 
recorded (FINAPRES, Ohmeda) and then digitally converted using a desktop computer. BRS was 
calculated by two experienced investigators (Prof Emilio Vanoli and Dr. Maria Teresa La Rovere) 
independently and blind to each other’s measurements. BRS was determined in 75 individuals from 
this founder population. Age has an important influence on BRS (29) and, indeed, in the 75 subjects 
under study whose age range was 16-65 years there was a significant (p < 0.001) negative 
correlation between age and BRS (r = 0.67). Accordingly, we focused our analysis on the 2nd and 
3rd age quartiles that included 38 subjects (age 26-47) and represented the middle 50% of the tested 
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population. In this group the correlation with age was not significant (see Results). This approach 
allowed a reliable assessment of BRS while controlling for the age effect. 
 
Statistical Analysis 
Comparisons of groups identified on the basis of the clinical characteristics and genotype 
were performed in univariate analysis. Student’s t-test or Mann-Whitney U test, as appropriate, 
were used for continuous variables and Fisher’s exact test was used for categorical variables. QTc 
duration and heart rate in MCs were divided in tertiles and the upper tertile of each variable, 500 ms 
and 73 bpm respectively, was used as a clinical risk factor. To determine the association of the 
selected clinical variables with the occurrence of cardiac events, odds ratios (OR) for unadjusted 
data and their 95% confidence intervals (95% CI) were calculated.  
The change in heart rate and in BRS values produced by BB was evaluated by the paired-
samples t test procedure or by the Wilcoxon signed rank test. To estimate the risk of cardiac events 
associated with predetermined values of BRS, this variable was dichotomized at the first tertile of 
its distribution in the populations under study. Odds ratios (ORs) with 95%CI was estimated by 
logistic regression. 
Time to the first cardiac event (syncope, cardiac arrest or sudden cardiac death) before 
initiation of β-blocker therapy and before age 40, was determined by Kaplan-Meier cumulative 
estimates. The South African A341V population (SA-A341V) was compared with the largest 
published data set on 355 LQT1 patientsP P(30), referred here to as the LQT1 database. The age-
related probability of surviving a first cardiac event was described by QTc, gender, and by the 
specific genetic defect. 
 The contribution of heart rate, QTc duration and gender to the risk of experiencing a cardiac 
event was determined by a logistic regression model where the presence or absence of a clinical 
history of cardiac events was used as the dependent variable. Odds ratios and 95% CI were 
computed while controlling for the covariates introduced in the model. 
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Data are reported as mean and standard deviation (SD) for continuous variables; whenever 
the distribution was skewed, median and interquartile range (IQR) were reported. Two-sided p-
values <0.05 were considered statistically significant. Statistical calculations were performed by 
using SPSS software (version 12). 
 
Site-Directed Mutagenesis 
Italian LQT2 Family (IT-A1116V) 
The two alleles identified in this study, A1116V and K897T, were constructed in a 
recombinant HERG cDNA using PCR site-directed mutagenesis (31). The final constructs were 
assembled in bicistronic mammalian expression plasmids (pIRES2-EGFP, pIRES2-DsRed, BD 
Biosciences-Clontech, Palo Alto, CA) in tandem with an internal ribosomal entry site (IRES) and 
either enhanced green fluorescent protein (EGFP) or DsRed for use as indicators of successful 
transfection. All constructs were sequenced to verify the mutation and to exclude polymerase errors. 
Wild-type HERG and the variant alleles were subcloned into pIRES2-EGFP and pIRES2-DsRed for 
use in co-expression experiments. 
South African LQT1 Founder Population (SA-A341V) 
Three mutations (A341V, G314S, 543 del/ins) were constructed in a recombinant human 
KCNQ1 cDNA by using polymerase chain reaction mutagenesis (primer sequences available on 
request). G314S produces a severe in vitro phenotype caused by a strong dominant negative effect, 
while 543 del/ins displays no dominant negative effectP P(32,33). All constructs were assembled in the 
bicistronic pIRES2-EGFP vector (BD Biosciences/Clontech, Palo Alto, CA) for mammalian cell 
expression experiments then verified by restriction mapping and DNA sequencing. Expression of 
KCNQ1 is driven by the CMV immediate-early promoter and enables simultaneous expression of 
enhanced green fluorescent protein from the same plasmid to mark transfected cells. 
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Cell Culture and Electrophysiology 
Italian LQT2 Family (IT-A1116V) 
 Chinese hamster ovary cells (CHO-K1, ATCC) were grown at 37°C in 5% CO2 in F-12 
nutrient mixture medium supplemented with 10% fetal bovine serum (FBS, ATLANTA  
Biologicals, Norcross, GA, USA), 2 mM L-glutamine, and penicillin (50 units/ml)- streptomycin 
(50 µg/ml). Unless otherwise stated, all tissue culture media was obtained from Life Technologies 
(Grand Island, NY, USA). Cells were transiently transfected using Fugene-6 (Roche Diagnostics, 
Indianapolis, IN) with 3 µg plasmid DNA. In co-expression experiments, cells were co-transfected 
with 3 µg of each plasmid. Following transfection (48-72 hours), fluorescent cells were selected by 
epifluorescence microscopy (green for single transfections, yellow for co-transfections) for use in 
whole-cell patch clamp recording experiments. Non-transfected CHO cells grown under these 
conditions did not exhibit measurable endogenous potassium currents with the recording conditions 
employed for this study. 
Whole-cell currents were measured in the broken-patch, whole-cell configuration of the 
patch clamp technique (34) using an Axopatch 200B amplifier (Axon Instruments Inc., Foster City, 
CA, USA). The bath solution consisted of (in mM): NaCl 145, KCl 4, MgCl2 1, CaCl2 1.8, glucose 
10, HEPES (N-[2-hydroxyethyl]piperazine-N’-[2-ethanosulfonic acid) 10, adjusted to pH 7.35 with 
NaOH, ~275 mosmol/kg. The pipette solution consisted of (in mM): KCl 110, ATP-K2 5, MgCl2 2, 
EDTA (ethylenediaminetetraacetic acid) 10, HEPES 10, adjusted to pH 7.2 with KOH, ¡«265 
mosmol/kg. The pipette solution was diluted 7-10% with distilled water to prevent activation of 
swelling-activated currents. Patch pipettes were pulled from thick-wall borosilicate glass (World 
Precision Instruments, Inc., Sarasota, FL, USA) with a multistage P-97 Flaming-Brown 
micropipette puller (Sutter Instruments Co., San Rafael, CA, USA) and fire-polished. Pipette 
resistance was 1-4 M., and as reference electrode, a 1-2% agar-bridge with composition similar to 
the bath solution was utilized. Whole-cell current traces were filtered at 5 kHz and acquired at 1-2 
kHz. All chemicals were purchased from SIGMA Chemicals (St. Louis, MO, USA). 
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The holding potential was –80 mV and whole-cell currents were measured from -80 to +70 
mV (in 10 mV steps) 1990 ms (activation) and 2200 ms (tail currents) after the start of the voltage 
pulse. The access resistance and apparent membrane capacitance were estimated as described by 
Lindau and Neher (35). Pulse generation, data collection and analyses were done with Clampex 8.1 
(Axon Instruments, Inc.). Statistical comparisons were made using Student's t-test and significance 
was assumed for P < 0.05. 
South African LQT1 Founder Population (SA-A341V) 
Mutant KCNQ1 plasmids were expressed in a Chinese hamster ovary cell line (CHO-K1, 
CRL 9618, American Type Culture Collection, Rockville, MD, USA) stably expressing wildtype 
KCNQ1 and its ancillary subunit KCNE1 to generate the repolarizing current IBKs B, as previously 
describedP P(36). This IBKs B cell line was generated by stable integration of a bicistronic KCNE1-IRES2-
KCNQ1 cassette by using targeted homologous recombination mediated by Flp recombinase. This 
approach enabled uniform expression of KCNQ1 and KCNE1 from a single genomic locus and 
resulted in a consistent level of current in all cells. Cells were grown at 37°C in 5% COB2 Bin F-12 
nutrient mixture medium supplemented with 10% fetal bovine serum (FBS, ATLANTA 
Biologicals, Norcross, GA, USA), 2 mM L-glutamine, penicillin (50 units/ml)-streptomycin (50 
μg/ml), and 600 μg/ml hygromycin. All tissue culture media was obtained from Life Technologies 
(Grand Island, NY, USA). Cells were transiently transfected by using Fugene-6 (Roche Diagnostics 
Corp, Indianapolis, IN). Following transfection (48-72 hours), fluorescent cells were selected by 
epifluorescence microscopy for use in whole-cell patch clamp recording experiments.  
Whole-cell currents were measured in the whole-cell configuration of the patch clamp 
techniqueP P(37) by using an Axopatch 200B amplifier (Axon Instruments Inc., Foster City, CA). The 
bath solution consisted of (in mM): NaCl 132, KCl 4.8, MgCl B2 B 1.2, CaCl B2B 2, glucose 5, HEPES (N-
[2-hydroxyethyl]piperazine-N’-[2-ethanosulfonic acid) 10, pH=7.4, ∼275 mosmol/kg. The pipette 
solution consisted of (in mM): K-aspartate 110, ATP-K B2 B 5, MgCl B2B 1, EGTA (ethylene glycol-bis-[β-
aminoethyl ether] 11, HEPES 10, MgCl B2B 1, pH=7.3, ∼265 mosmol/kg. The pipette solution was 
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diluted 7-10% with distilled water to prevent activation of swelling-activated currents. Patch 
pipettes were pulled from thick-wall borosilicate glass (World Precision Instruments, Inc., Sarasota, 
FL) with a multistage P-97 Flaming-Brown micropipette puller (Sutter Instruments Co., San Rafael, 
CA) and fire-polished. Pipette resistance was 1-4 MΩ, and as reference electrode, a 1-2% agar-
bridge with composition similar to the bath solution was utilized. Whole-cell current traces were 
filtered at 5 kHz and acquired at 1-2 kHz. All chemicals were purchased from SIGMA Chemicals 
(St. Louis, MO). 
The holding potential was –80 mV and whole-cell currents were measured from –80 to +60 
mV (in 10 mV steps) 1990 ms after the start of the voltage pulse. The access resistance and 
apparent membrane capacitance were estimated as described by Lindau and NeherP P(38). Pulse 
generation, data collection and analyses were done with Clampex 8.1 (Axon Instruments, Inc.) and 
SigmaPlot 7.0 software suites. 
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RESULTS: Italian LQT2 Family (IT-A1116V) 
Clinical Phenotype 
The proband had palpitations associated with pre-syncopal episodes since age 20, and a 
cardiac arrest due to ventricular fibrillation at age 44. The patient had no exposure to medications 
with pro-arrhythmic effects. No specific trigger for the episode of cardiac arrest was identified, as 
she was quietly sitting in the car while her husband was driving. Subsequent investigations 
including brain and chest CT scans, echocardiography, coronary angiography, cardiac magnetic 
resonance imaging, a standard clinical electrophysiological study and flecainide challenge test were 
all normal. Shortly after cardiac arrest serum potassium was 3.5 mEq/L, but was subsequently 
found to be in the normal range. A surface resting ECG was normal with a QTc of 425 msec. A 
diagnosis of idiopathic ventricular fibrillation was made, prompting implantation of an internal 
defibrillator (ICD) and initiation of beta-blocker therapy.  
During a follow-up 12-lead 24-hour ECG recording, periods of bifid T waves in leads V3-
V5 and prolonged QTc (maximum QTc 530 ms) were observed (Fig. 1). During most of the 
recording, however, the morphology and QTc duration were normal indicating that the patient had a 
labile QT interval. An exercise stress test showed a normal rate adaptation of ventricular 
repolarization: in basal condition, at a heart rate of 77 bpm, QTc was 450 ms and did not increase at 
peak exercise when heart rate reached 111 bpm. A subsequent ECG showed a basal QTc of 470 ms 
with negative T-waves in lead V3-V4, but a prolonged QTc up to 510 ms in V3 during a 
hyperventilation test (Fig. 2). Family history was negative for syncope or sudden cardiac death, 
although one sibling of the proband was a stillborn.  
 
Identification of a Novel KCNH2 Mutation 
We screened DNA from the proband for mutations in all coding exons of KCNQ1, KCNH2, 
SCN5A, KCNE1 and KCNE2 using DHPLC. An abnormal elution profile was identified in one 
fragment encompassing KCNH2 exon 15 amplified from the proband, but this was not observed in 
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130 control Caucasian individuals. Sequence analysis revealed a heterozygous missense mutation 
that results in an alanine to valine substitution at position 1116 (designated A1116V, Fig. 3A). This 
amino acid lies within the distal carboxyl-terminus of the encoded protein (HERG) and is highly 
conserved among homologous sequences of several species including human, mouse, rat and dog 
(Fig. 3B). A second KCNH2 variant (K897T) was identified in the proband. This is a common 
polymorphism with an estimated prevalence in Caucasian populations up to 33% (39-41). 
 
Segregation of KCNH2 Variants 
Segregation of A1116V and K897T in the proband’s family indicates that the two variants 
are located on separate KCNH2 alleles (Fig. 4). Mutation screening revealed that A1116V, but not 
K897T, was present in a brother and in his two children. All A1116V carriers other than the 
proband were asymptomatic with normal baseline QT intervals (Fig. 5). Twelve-lead 24-hour 
Holter recordings were completely normal in the brother (Fig. 5B) and showed rare transient 
episodes of mild QTc prolongation in a 22-year-old niece (maximum QTc 480 ms, Fig. 5C). A 9-
year-old nephew had a borderline normal QTc during most of the recording, but brief periods of 
biphasic or notched T waves in leads V3-V4 and prolonged QTc in all leads were observed (Fig. 
5D). However, the QTc was always less than 500 ms in the nephew and QTc prolongation occurred 
only during periods of increased heart rate. The hyperventilation test was normal in the brother but 
induced QT prolongation in both niece (maximum QTc 490 ms) and nephew (maximum QTc 480 
ms). The hyperventilation test is a useful clinical tool able to increase the sensitivity of standard 
ECG in detecting mutation carriers (42). The K897T polymorphism was also identified in the 
proband’s son and in one of her sisters. Both of these K897T carriers were asymptomatic with 
normal QTc intervals by standard ECG and during the hyperventilation test. One of the proband’s 
brothers refused medical contact. The genetic status of her parents could not be ascertained because 
they were deceased. 
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Biophysical characterization of KCNH2 variants 
We studied the functional features of both variants separately and together using whole-cell 
patch clamp recording of recombinant HERG heterologously expressed in cultured CHO-K1 cells. 
Functional characterization of A1116V revealed significantly reduced activating and tail current 
densities at positive potentials when compared to wildtype HERG (WT-HERG) (Fig. 6A-C, P < 
0.05). Similarly, expression of K897T generated current densities that were significantly less than 
WT-HERG at potentials greater than +10 mV (Fig. 6B,C, P < 0.05). Tail current density was 50% 
lower in cells expressing A1116V compared to cells expressing WT-HERG, but only 25% lower in 
cells expressing K897T (Fig. 6C). 
Comparing the two variants to one another, activating and tail current densities for A1116V 
were significantly less than K897T at positive potentials (Fig. 6B,C, P < 0.05). A significant shift in 
the voltage-dependence of activation was also observed for A1116V (V1/2, –5.1 ± 2.4 mV) 
compared to WT-HERG (V1/2, +1.1 ± 1.7 mV; Fig. 6D, P < 0.05) but there was no significant shift 
observed for K897T. More detailed analyses of kinetic properties demonstrated that A1116V 
exhibits slower recovery from inactivation, whereas the time course and voltage-dependencies of 
inactivation and deactivation where indistinguishable among the three alleles. We conclude that 
both A1116V and K897T cause mild channel dysfunction, but A1116V has greater functional 
impairments. 
Because the proband carried both A1116V and K897T on separate alleles, we examined the 
effects of co-expressing both variants in the same cells. To demonstrate expression of both 
constructs in a single cell, we coupled expression of the variant HERG alleles to either EGFP or 
DsRed fluorescent proteins using bicistronic IRES vectors, and identified co-expressing cells by 
yellow fluorescence (combined EGFP and DsRed). Coexpression of either A1116V or K897T with 
WT-HERG did not significantly alter the magnitude of activating currents (Fig. 7A). By contrast, 
cells co-expressing A1116V and K897T together exhibited significantly lower current density 
compared to WT-HERG alone at potentials greater than –10 mV. Current density at positive 
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potentials was also lower in cells co-expressing both variant alleles compared with co-expression of 
A1116V or K897T with WT-HERG (Fig. 7A). Tail current density was significantly lower in cells 
co-expressing A1116V and K897T compared to WT-HERG alone, co-expression of K897T and 
WT-HERG, and co-expression of A1116V and WT-HERG at positive potentials (Fig. 7B). There 
was no significant shift in the voltage-dependence of activation observed in any of these 
experiments (Fig. 7C). Based upon these findings, we determined that the K897T polymorphism 
exaggerates the reduction in IKr caused by A1116V. 
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FIGURES: Italian LQT2 Family (IT-A1116V) 
 
Figure 1: ECG recordings from the proband. The morphology and QTc duration were normal 
during most of the recording (A); however, there were also transient episodes of bifid T waves in 
leads V3-V5 (B) and prolonged QTc (maximum QTc 530 ms) (C). 
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Figure 2. Hyperventilation test in the proband. The baseline ECG showed a QTc of 470 msec 
with negative T waves in V3-V4; During hyperventilation QTc prolonged to 510 ms in V3 and the 
repolarization abnormalities were magnified. QTc represents the mean value of five consecutive 
beats. 
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Figure 3. Identification of KCNH2-A1116V. (A) DNA sequence chromatogram showing a 
heterozygous mutation (C to T transition) resulting in an alanine to valine substitution at codon 
1116. (B) Alignment of HERG amino acid sequence from various species illustrating that alanine at 
position 1116 is highly conserved. 
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Figure 4. Segregation of A1116V and K897T in the LQTS pedigree. Analysis of the pedigree 
indicates that the two variants exist on separate KCNH2 alleles. Family history was negative for 
syncopal events or sudden cardiac death, though one of the proband’s siblings was stillborn in the 
9th month of pregnancy. 
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Figure 5. Characteristics of asymptomatic KCNH2-A1116V carriers. (A) Partial family tree 
from Figure 3. The A1116V mutation, but not K897T, was identified in one brother and his two 
children. (B) Normal QTc in the brother recorded during 12-lead 24-hour ECG monitoring. (C) The 
22-year-old niece had a normal baseline QTc, but during a 24-hour ECG recording, rare transient 
episodes of mild QTc prolongation were observed (maximum QTc 480 ms). (D) The 9-year-old 
nephew had a normal baseline QTc, but during 24-hour ECG recording, periods of biphasic or 
notched T waves in leads V3-V4 and prolonged QTc were observed. However, QTc was always 
less than 500 ms and prolongation occurred only during increased heart rate. 
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Figure 6. Functional characterization of A1116V and K897T HERG variants. (A) 
Representative traces illustrating potassium currents observed in CHO cells transiently transfected 
with WT-HERG or A1116V (horizontal and vertical scale bars represent 1000 ms and 225 pA, 
respectively). (B) Current-voltage relationship for potassium current densities (normalized to 
membrane capacitance) measured in CHO cells expressing WT-HERG (WT, solid circles, N = 9), 
K897T (open circles, N = 9), or A1116V (solid squares, N = 8). (C) Current-voltage relationship for 
amplitude of peak tail current densities following repolarization to –50 mV for WT-HERG (WT, 
solid circles, N = 9), K897T (open circles, N =9), or A1116V (solid squares, N = 8). (D) Normalized 
current-voltage relationship for peak tail current densities for WT-HERG (WT, solid circles, N = 9), 
K897T (open circles, N = 9), or A1116V (solid squares, N = 8). Data were recorded at test 
potentials ranging from –80 to +70 mV stepped in 10 mV increments from the holding potential of 
–80 mV for 2000 ms, followed by repolarization to –50 mV for 2000 ms. Data are shown as means 
± SEM. 
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Figure 7. Co-expression of HERG variants. Plasmids encoding WT-HERG, A1116V or K897T 
were expressed in tandem with either EGFP or DsRed. In each experiment, the allele listed first in 
the inset legend is coupled to EGFP, while the second is coupled to DsRed. (A) Current-voltage 
relationship for potassium currents (normalized to membrane capacitance) measured in CHO cells 
co-expressing WT-HERG + WT-HERG (closed circles, N = 9), K897T + WT-HERG (open circles, 
N = 9), A1116V + WT-HERG (closed triangles, N = 10), or A1116V + K897T (open triangles, N = 
10). (B) Current-voltage relationship for peak tail current densities after repolarization to –50 
mV(C) Normalized current-voltage relationship for peak tail current densities. Data are shown as 
means ± SEM. Significant differences between A1116V + K897T and WT-HERG + WT-HERG are 
denoted by *, while significant differences between A1116V + K897T and A1116V + WT-HERG 
are denoted by # (P < 0.05). 
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RESULTS: South African LQT1 Founder Population (SA-A341V) 
Family Ascertainment, Genealogy, and Genotyping 
A LQTS founder population (SA-A341V) consisting of 22 apparently unrelated kindreds 
was ascertained in South Africa. All index cases could be traced to a single founding couple, of 
mixed Dutch and French Huguenot origin, who married in approximately 1730 (Fig. 8). The disease 
associated haplotypes of index cases strongly support the founder hypothesis (Fig. 8). 
Of 345 individuals in the study population, 166 were mutation-carriers, 154 were non-
carriers and 25 were not genetically tested (Fig. 9). 
 
Clinical Phenotypes 
Among the 166 MCs, females (54%) and males were similarly represented. According to 
definitions reported in the Method Session (page 5 and 6), 131 (79%) were symptomatic with a 
median age at first cardiac event of 6 years (IQR 4-10), and 23 (14%) suffered sudden cardiac death 
before age 20. The 26 patients here defined as asymptomatic were those older than 15 years with no 
events. Nine other patients without events were too young (age <15) to be designated as 
asymptomaticP P(43) 
Among the 166 MCs, a basal ECG without beta-blocker therapy was available in 92, while 
74 had no ECG data. The two subgroups were no significant different in terms of  gender (females: 
59% in patients with an ECG, vs 47% in patients without an ECG;  p=0.16), cardiac events 
(Symptomatic MCs: 74% vs 85%, p=0.09) and age at first event (7.39±4 vs 7.13±4 years; p=0.7); 
however, none of the 23 sudden cardiac death had an ECG available. Eighty-six MCs and 102 non-
carriers, with a basal ECG recorded after age 15 (Fig. 9), were analyzed for differences in QTc 
interval, heart rate and symptoms. Baseline QTc was longer in MCs than in non-carriers (487±45 vs 
401±25 ms, p<0.001; Fig. 10). Despite sharing the same genetic defect, mutation-carriers as a group 
exhibited a wide range of QTc values (406-676 ms) with 12% of individuals having a normal QTc 
(≤440 ms). QTc was longer among symptomatic as compared with asymptomatic MCs (493±48 vs 
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468±31 ms, p=0.026; Fig. 11). A QTc≥500 ms was associated with an increased risk of 
experiencing cardiac events (OR=4.22; 95% CI 1.12-15.80; p=0.033). 
Because IBKs B magnitude is rate-dependent, we examined the role of HR as a predictor of 
events. Baseline HR was not different between MCs and non-carriers (69±12 vs 70±11 bpm). The 
baseline heart rate of symptomatic MCs was also very similar to that of non-carriers (71±11 vs 
70±11 bpm). By contrast, asymptomatic carriers had a significantly lower heart rate compared to 
symptomatic individuals (65±13 vs 71±11 bpm, p=0.026). Mutation carriers in the lowest 2 tertiles, 
defined by HR <73 bpm, were at lower risk for cardiac events compared to those with in the highest 
tertile, HR ≥73 bpm (OR=0.23; 95% CI, 0.06-0.86; p=0.035). There was no correlation between age 
and HR. We performed multivariate analyses to determine the clinical variables (HR, QTc, gender) 
best predicting risk for cardiac events in the SA-A341V population. We considered HR and QTc as 
categorical variables with the same cut-off used in univariate analysis. Both QTc≥500 ms 
(OR=4.98; 95% CI, 1.21-20.55; p=0.026) and HR≥73 (OR=4.11; 95% CI, 1.03-16.44; p=0.046) 
were found to be significant risk factors for experiencing cardiac events after controlling for other 
covariates included in the model. Gender was not an independent risk factor in our analysis. 
Results from both univariate and multivariate analyses identify HR and QTc as important 
factors in determining disease expression in this population. Figure 12 presents the distribution of 
symptomatic and asymptomatic MCs among four quadrants defined by cut-off values of HR and 
QTc. The smallest proportion of symptomatic subjects was found in the quadrant defined by HR<73 
bpm and QTc<500 ms. In this subgroup, the risk of cardiac events was significantly lower than for 
all other subjects combined (OR=0.19; 95% CI, 0.06-0.59; p=0.005). However, there was still a 
significant risk of cardiac events in this subgroup as most subjects (60%) represented in this 
quadrant were symptomatic. Interestingly, the impact of HR in risk-stratification was stronger in the 
subgroup of patients with a QTc<500 ms compared to that with a QTc≥500 ms. Indeed, there was a 
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linearly increasing proportion of symptomatic mutation-carriers from the lower to the upper tertile 
of heart rate representing an incremental risk (OR=2.5; 95% CI, 1.11-5.62; p=0.026) (Fig. 13). 
 
Baroreflex Sensitivity and Risk for Cardiac Events 
As explained in the Methods the analysis of BRS was limited to subjects in the two middle 
age quartiles (26-47 years) to avoid the influence of age (29). Indeed, within this group (n= 38) 
there was no correlation between BRS and age (r = -0.17, NS). Furthermore, even subdividing this 
group according to the median value (36 years) there was no difference in BRS across the two 
subgroups. 
The mean value of BRS in the entire group of 38 subjects was 16.7 ± 8.8 ms/mmHg. As 
expected by a distribution of autonomic parameters independent of the LQTS mutation, the BRS 
values between MCs (n = 22) and non-MCs (n = 16) were not different (17.1 ± 9.7 vs 16.3 ± 7.6, 
NS) (Fig. 14A). By contrast, a significant difference emerged when the analysis compared the 
asymptomatic (n = 8) to the symptomatic (n = 14) MCs (11.8 ± 3.5 vs 20.1 ± 10.9; p = 0.04) (Fig. 
14B). A BRS ≤12 ms/mmHg, which corresponds to the first tertile of the distribution among all the 
38 subjects, carried a significantly lower risk of suffering cardiac events compared to a BRS in the 
upper two tertiles (OR 0.13, 95%CI 0.02-0.96, p < 0.05) (Fig. 14B). Indeed, among MCs with a 
BRS > 12 ms/mmHg, 10 of 12 (83%) subjects were symptomatic. BRS values in the first tertile, 
which represents the lower end of the spectrum of normal values among these South African 
families, will be referred to as “relatively low”.  
When we assessed whether the level of BRS was associated with differential risk for 
arrhythmic events in the 15 patients with a QTc ≤ 500 ms we found that none of the MCs in the first 
tertile (BRS ≤ 12ms/mmHg) had cardiac events whereas 80% of those with a BRS >12 ms/mmHg 
were symptomatic (p < 0.01) (Fig. 15). 
The subgroup of MCs with BRS values without beta-blocker therapy is representative of the 
entire population of MCs, as there are no significant difference in terms of  gender (females: 57% in 
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patients with BRS, vs 52% in patients without BRS;  p=0.6), cardiac events (Symptomatic MCs: 
74% vs 81%, p=0.4) and age at first event (7.16±3.7 vs 7.31±4 years; p=0.84). 
In 22 of these 38 subjects we assessed BRS both on and off BB and observed that treatment 
significantly increased BRS by 5 ± 8 ms/mmHg (p < 0.05). Importantly, this effect was not uniform 
across the three subgroups (non-MCs, symptomatic and asymptomatic MCs). Indeed, while a trend 
for greater BRS during BB was evident in both symptomatic MCs and non-MCs (4.5 ± 7 and 9 ± 11 
ms/mmHg, respectively) it was practically absent in asymptomatic subjects (0.83 ± 7 ms/mmHg) 
(Fig. 16). Among MCs on BB treatment and with a BRS above the lower tertile (14 ms/mmHg), 7 
of 8 (87.5%) subjects had symptoms, a similar proportion to that observed off BB (83% with 
symptoms, among those with a BRS above the lower tertile). 
 
 
Clinical Severity in the South African LQTS Population 
As our ascertainment revealed relatively few asymptomatic patients in the SA-A341V 
population, and 14% incidence of sudden death before age 40, we considered the possibility that the 
KCNQ1-A341V mutation segregating in these families might be associated with a greater incidence 
of cardiac events compared to that reported for LQT1 subjects in general. To test this hypothesis, 
we compared clinical severity between the SA-A341V and LQT1 populationsP P(30). In our 
population, the availability of information for 161 KCNQ1-A341V MCs, including 126 who were 
symptomatic, allowed us to analyze the cumulative event-free survival (Kaplan-Meier analysis) 
before the institution of β-blocker therapy and before age 40. Five MCs were not included in the 
analysis because time to first event was not available.  
Compared to the LQT1 population, the SA-A341V group exhibited a more severe form of 
the disease. The SA-A341V carriers became symptomatic earlier than LQT1 (7±4 vs 13±9 years, 
p<0.001), with a 79% incidence of a first cardiac event by age 40 compared with 30% observed for 
LQT1 (p<0.001). As shown in Fig. 17, the cumulative probability of suffering a first cardiac 
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episode before initiating β-blocker therapy and before age 40 was significantly greater (p<0.0001) 
for the SA-A341V population, in which the event-free survival is 20% by age 15 as compared with 
80% for the LQT1 database. 
Our findings on the clinical severity of the SA-A341V phenotype could be partly explained 
by the significantly lower prevalence of MCs with a QTc<440 ms in this population as compared to 
the LQT1 database (12% vs 36%, p<0.001). This in turn can account for the longer QTc measured 
in MCs in our population (487±45 vs 466±44 ms, p<0.001). Because of this concern, we performed 
separate Kaplan-Meier estimates of cardiac event free survival for groups distinguished by QTc. 
Furthermore, to avoid the confounding role of patients with QTc<440 ms, we restricted our analysis 
to subjects with QTc≥500 ms. We also constructed Kaplan-Meier curves separately by gender and 
observed that they were similar for males and females. As the time course of events is much more 
rapid for LQT1 males, who have their events earlier in time, and as in our population the number of 
males available for this analysis was small we have chosen not to combine data for males and 
females and to present in Fig. 18 only the data based on the larger and more homogenous female 
group (n=24). These analyses support the finding that the clinical severity of LQTS observed in the 
SA-A341V population is significantly greater than LQT1 in general. 
To further support the  finding, we compared our SA-A341V population also to the one 
reported by Zareba et alP P(19) even though it included only 112 patients from 10 families (Fig.19). 
This was done because Zareba’s population had an average QTc very similar to that of the SA-
A341V patients (490±43 vs 487±45 ms). The Kaplan-Meier curves remained significantly different 
(p<0.01) as significant were the difference of patients with a first event by age 15 (55% vs 80%, 
p<0.001) and the difference in mortality (2% vs 14%, p<0.001). This conclusively demonstrates the 
unusual clinical severity associated with A341V. 
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Functional characterization of KCNQ1-A341V 
Previous studies have characterized the KCNQ1-A341V mutation in Xenopus oocytesP P(44-
46) or COS7 cellsP P(47). These studies reported that this allele is a simple loss-of-function mutation 
that does not exhibit a dominant-negative effect on WT KCNQ1 suggesting that it may cause less 
severe disease. However, oocytes express an endogenous Xenopus KCNQ1 (48) and multiple 
KCNE accessory subunitsP P(49). Accordingly, and in light of our observation that South African 
LQTS families segregating KCNQ1-A341V have a severe clinical phenotype, we reassessed the 
functional consequences of this allele in a cultured mammalian cell system. In these experiments, 
we recognized the need to verify co-expression of WT and mutant KCNQ1 along with the KCNE1 
accessory subunit, a potential confounding variable for interpreting previously-reported COS7 cell 
dataP P(47). Therefore, we transiently transfected KCNQ1-A341V-IRES-EGFP into CHO cells stably 
expressing consistent levels of WT KCNQ1 with KCNE1 (stable IBKs B cell line). We then performed 
whole-cell patch clamp recording on cells exhibiting green fluorescence i.e. cells coexpressing both 
A341V and both subunits for IBKs B (Fig. 20). Cells transiently transfected with the empty pIRES2-
EGFP expression vector exhibited slowly activating outward current consistent with IBKs B. Co-
expressing KCNQ1-A341V in these cells reduced the magnitude of IBKs B by approximately 50%. By 
comparison, co-expression of a recessive LQTS mutant (543-del/ins) had no effect on IBKs B amplitude, 
whereas a strong dominant LQTS mutation (G314S) suppressed current by approximately 70% at 
positive voltages. These results demonstrate that KCNQ1-A341V exerts dominant suppression of 
I BKs Bto an extent slightly less than a strong dominant mutation but behaves in a manner distinct from 
a pure loss-of-function allele. 
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FIGURES: South African LQT1 Founder Population (SA-A341V) 
Figure 8: Lines of descent of the KCNQ1-A341V mutation from a common founder couple P 
are shown. The haplotype that segregates with the mutation is consistent with a common origin of 
the mutation and with minimal recombination over 10 generations. Genealogical information for 
pedigree 170, in which the common haplotype segregates and for pedigree 180, a single individual, 
could not be found. As phase could not be determined for the latter, maternal and paternal alleles at 
D11S4046 and D11S1318 are shown. Haplotypes were constructed from the results of the 
combination of alleles inherited at D11S4046, D11S1318, A341V, D11S4088, D11S4146, 
D11S4181, D11S1871, D11S1760, D11S1323 in the order telomere to centromere. Common 
haplotypes are bordered. Index cases are shown as diamonds to preserve anonymity. Circles denote 
females and squares males in the line of descent. Ped=pedigree. Year of birth is shown below 
individuals. The letters P, Q, T refer to couples in the first two generations from which the mutation 
descended. 
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Figure 9: Flow-chart with the number of subjects, divided by subgroups in the study 
population. An ECG off BB therapy was available in 93 MCs, of these 86 were recorded after 15 
years of age and were used for ECG analysis. Appropriate data for survival analysis were available 
for 161/166 MCs; of these, an ECG off ß-blocker therapy was available in 89. 
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Figure 10: Basal QTc in mutation and non-mutation carriers. The long horizontal line 
represents the upper limit of normal values for men (440 ms). The short horizontal lines represent 
the mean. In two MCs and in three NMCs the QTc was not measurable because of the presence of 
bundle branch block. 
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Figure 11: Basal QTc in symptomatic and asymptomatic mutation carriers. The long 
horizontal line represents the upper limit of normal values for men (440 ms). The short horizontal 
lines represent the mean.  
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Figure 12: Distribution of mutation-carriers according to symptoms, HR and QTc. The cut-off 
at 500 ms and at 73 bpm represent the upper tertile. 
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Figure 13: Percentage of symptomatic patients with a basal QTc < 500 ms in each tertile of 
heart rate.  The cut-off at 500 ms and at 73 bpm represent the upper tertile. 
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Figure 14: BRS values off-BB in different groups. BRS values off-BB in the entire group under 
study aged 26-47 years divided in MCs and in non-MCs (4A), and in symptomatic and 
asymptomatic MCs (4B). Mean and standard deviation are shown for each subgroup. The dashed 
horizontal line represents the lower tertile of BRS values. 
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Figure 15: Distribution of mutation-carriers according to symptoms, BRS and QTc. The cut-
off at 500 ms of QTc represents the upper tertile.  The cut-off at 12 msec/mmHg of BRS represents 
the lower tertile.  
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Figure 16: Effect of BB therapy on BRS. The increase in BRS during BB therapy was evident in 
symptomatic MCs, but it was practically absent in asymptomatic MCs. 
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Figure 17: Kaplan-Meier curves of event-free survival in the LQT1 database (from ref. 30) 
population and in the SA-A341V population. The numbers under the curves represent subjects at 
risk. 
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Figure 18: Kaplan-Meier curves of event-free survival among females with a QTc ≥ 500 ms 
from the LQT1 database (from ref. 30) and from the SA-A341V population. 
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Figure 19: Comparison between the SA-A341V and the LQT1 population as reported by 
Zareba et al (19). The Kaplan Meier estimate of the cumulative probability of a cardiac event in 
the LQT1 group was obtained by reconstructing  the original curve based on the information 
reported in the paper by Zareba et. al. Numbers above curves represent the cumulative probability 
of a cardiac event at 5, 10, 15 and 40 years for both curves. Numbers above the Zareba’s curve and 
the corresponding number of patients at risk (bottom) were obtained by reconstructing the curve.  
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Figure 20: Functional characterization of KCNQ1-A341V. Whole-cell patch clamp recording of 
heterologously expressed KCNQ1 mutations in stable IBKs Bcells. Representative current records 
obtained from I BKs Bcells co-expressing vector alone (EGFP), A341V, 543del/ins or G314S (17A). 
Current-voltage relationships for mutant KCNQ1 channels expressed in IBKs B cells. Current is 
normalized to cell capacitance. Statistical differences (P<0.05) in current densities between IBKs B + 
EGFP and I BKs B + A341V are indicated by single asterisks. Statistical difference (P<0.05) between I BKs B 
+ G314S and I BKsB + A341V is indicated by a double asterisk (20B). 
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DISCUSSION: Italian LQT2 Family (IT-A1116V) 
The findings on the Italian LQT2 family provide clinical, molecular and in vitro 
electrophysiological evidence that a very common KCNH2 polymorphism can act as a genetic 
modifier of the clinical severity of the long QT syndrome. 
The genetic basis of symptomatic and apparently sporadic LQTS in a middle-aged woman 
was determined to be a novel heterozygous missense mutation (A1116V) in KCNH2 co-segregating 
with the common KCNH2-K897T variant on the opposite allele. Other family members carrying 
only one of these variants were asymptomatic but some showed evidence of subclinical disease 
associated with A1116V. 
Biophysical characterization revealed that the degree of functional HERG impairment in the 
heterozygous condition for A1116V is relatively mild compared to other LQTS mutations causing 
the full phenotypic expression of LQTS. This is consistent with the concept that A1116V is 
associated with a latent form of LQTS. However, when co-expressed with K897T, a more 
substantial reduction in HERG activity was observed. These findings are concordant with the 
clinical observation that symptomatic LQTS occurred only in the proband carrying both variant 
alleles. Because K897T is a common polymorphism and by itself has not been associated with 
LQTS, we propose that this allele acts as a genetic modifier to promote the clinical expression of 
the disease caused by A1116V. 
 
Genetic Modifiers of LQTS 
Inherited disorders are said to exhibit incomplete penetrance when less than 100% of 
mutation carriers exhibit disease manifestations. This is very common in autosomal dominant 
LQTS and current wisdom posits the existence of modifier genes to partly explain this 
phenomenon. Despite widespread acceptance of this notion, there have been very few specific 
genetic modifiers identified in LQTS or other inherited arrhythmia syndromes. Ye and colleagues 
reported that H558R, a common SCN5A polymorphism present in 20-30% of Caucasians, modifies 
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the in vitro activity of the SCN5A-M1766L mutation when present together (50). These studies 
provided tenable mechanisms for intramolecular complementation but the practical significance of 
the data was limited by the absence of genetic evidence that the two variants occurred on the same 
allele in LQTS subjects. Homozygosity for SCN5A-H558R has also been shown to provoke 
conduction system disease associated with the mutation SCN5A-T512I in a young child (51). A 
related example involves the observation of atrial standstill associated with SCN5A-D1275N in a 
Dutch family cosegregating a common connexin-40 promoter haplotype (52). As discussed earlier, 
coinheritance of KCNQ1 mutations with the common variant KCNE1-D85N predisposes to greater 
degrees of QT prolongation and more severe symptoms in two of the families reported by 
Westenskow et al. (53). Inherited predisposition to hypokalemia caused by renal salt wasting has 
also been observed as an unusual form of genetic modification of LQTS associated with a KCNQ1 
mutation (54). 
Genetic factors other than the primary mutation may worsen the severity of LQTS or, as 
illustrated by the case we present here, expose latent disease. In the situation where a modifier allele 
unmasks an otherwise subclinical form of LQTS, the correct diagnosis is extremely difficult without 
the support of genetic testing and segregation analysis of the extended pedigree. Even identification 
of the novel A1116V mutation did not suffice in explaining the occurrence of LQTS in the proband 
we report here. Although the occurrence of ventricular fibrillation in the absence of physical 
exercise is consistent with the current knowledge regarding genotype-phenotype correlation in 
LQT2 (12,55), the location of the A1116V mutation (C-terminus) is usually associated with a mild 
or benign form of LQTS (56,57) rather than the presenting symptom of cardiac arrest observed in 
this case. Only when the co-inheritance of the common polymorphism K897T was considered did 
the genetic data coincide with clinical observations. 
The electrophysiologic characterization of A1116V and K897T, alone and in combination, 
provided additional evidence to support the hypothesis that co-inheritance of both variants is 
necessary for clinically overt disease. A1116V produces a significant, but less dramatic, reduction 
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in IKr than other LQTS-associated KCNH2 mutations. This is consistent with individuals carrying 
only A1116V exhibiting either a normal QTc or transient signs of modest QT prolongation. K897T 
also reduced IKr, but to a lesser degree than A1116V and only at a voltage of 10 mV or greater. Co-
expression of the two variants led to a significantly greater reduction of IKr compared to that 
produced by each individual allele. The reduction in IKr caused by the co-expression of A1116V 
and K897T was evident at voltages that are likely relevant to the membrane potential during the 
action potential plateau. This explains why the actual loss of repolarizing current was of sufficient 
magnitude to produce, even transiently, major QT prolongations and electrical instability in the 
proband. The functional studies reported here were performed in the absence of accessory subunits 
such as KCNE2. Recent experimental evidence has questioned whether KCNE2 acts as an obligate 
ß subunit for KCNH2 (58) and other investigations have demonstrated that this protein has very 
restricted cardiac expression (59,60). It is conceivable that co-expression of KCNE2 might 
influence the functional behavior of the KCNH2 mutant but the physiological relevance would be 
uncertain. 
 
Clinical and Functional Significance of KCNH2-K897T 
The KCNH2-K897T variant has previously attracted the interest of several investigators, but 
there has been inconsistent evidence for association of this allele with a clinical phenotype. This is a 
common SNP in Caucasians with a minor allele frequency of 24% (40) and 33% of the general 
population is heterozygous (32). The proportion of other ethnic groups that are heterozygous for 
K897T is lower (7-8% in Asian, Black and Hispanic populations) (39). 
This variant may have an impact on the QT interval. Pietila and colleagues (61) found that 
K897T was associated with longer QT intervals in middle-aged females. Similarly, Paavonen et al. 
(41) reported on a group of LQT1 patients all carrying the same KCNQ1mutation (G589D) who 
exhibited longer QT intervals upon exercise if they also carried the K897T allele. By contrast, 
Bezzina et al. (40) reported that QTc was shorter among control subjects homozygous for K897T. 
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Although the latter study surveyed a large population (N =1382), which increases the statistical 
power, the actual differences in QTc were rather small (10 ms). 
Similarly, previous heterologous expression studies to determine the functional impact of 
K897T are not in complete agreement. Anson et al. (62), using human embryonic kidney cells, 
observed several differences between K897T and WT-HERG channels. K897T channels activated 
at more negative potentials, inactivated and recovered from inactivation faster compared to WT 
channels. These authors proposed that the small decreases (10-30%) of current observed for K897T 
channels could cause a subtle increase in action potential duration. Using similar methodology, 
Paavonen and colleagues (41) reported a smaller current density, slower inactivation, and reduced 
expression of the K897T variant compared to wild type. The authors speculate that these changes 
could lead to increased arrhythmia susceptibility in settings of reduced repolarization. By contrast, 
Bezzina et al. (40) concluded that K897T might decrease action potential duration slightly leading 
to accelerated repolarization and shorter QT intervals based upon computer simulations 
incorporating their own electrophysiological observations. Finally, Scherer et al (63) found no 
difference between K897T and WT-HERG when experiments were performed in Xenopus oocytes. 
Our findings are consistent with the majority of the studies described above, particularly in 
that expression of the K897T variant resulted in slightly lower current density compared to WT-
HERG. Similarly to several of the previous studies, our work utilized cultured mammalian cells, 
however we used bicistronic IRES plasmids that enabled greater certainty in co-expression 
experiments. The small decreases in current density that we observed for K897T in both the 
homozygous and heterozygous states are not expected to cause disease alone, but may accentuate 
the effects of reduced repolarization reserve in certain settings such as QT-prolonging drugs or co-
inheritance of a LQTS mutation. 
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Implications for Risk Stratification in LQTS 
This study contributes to the “proof of concept” that common polymorphisms can act as 
genetic modifiers of the clinical severity in familial arrhythmogenic disorders. The novel and 
unexpected finding is that the clinical manifestations of LQTS can be exacerbated also by a 
polymorphism with a very high prevalence (30%) in the general population.  
The importance of this concept should not be underestimated. Clearly, other SNPs will be 
identified that are able to either increase or decrease the arrhythmic risk of patients affected by 
LQTS or other inherited arrhythmia syndromes. Furthermore, the present observation contributes to 
the search for modifier genes capable of modulating the risk for sudden death in more prevalent 
cardiac diseases (64). Relevant examples are acute myocardial infarction and congestive heart 
failure, two conditions burdened by a significant number of unexpected sudden cardiac deaths 
occurring either during the first few minutes of an ischemic episode or in patients with only modest 
degrees of pump failure. From a practical point of view, risk stratification of patients affected by 
LQTS (30) will have to consider the presence or absence of other SNPs, as well as K897T, as they 
are demonstrated to act as genetic modifiers. Molecular genetics integrated with clinical cardiology 
is progressively offering new clues for a better management of patients at risk for sudden death. 
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DISCUSSION: South African LQT1 Founder Population (SA-A341V) 
In the present study we analyzed a population of LQT1 patients, established in South Africa 
more than three centuries ago and sharing a mutation identical by descent caused by a founder 
effect, to begin defining factors capable of explaining phenotypic variability in this disease. We 
identified two autonomic markers, heart rate and baroreflex sensitivity, as novel factors determining 
risk for cardiac events in this LQT1 population. We also provided unexpected evidence for the 
unusual clinical severity manifested by carriers of the KCNQ1-A341V mutation in this population, 
and further demonstrated, contrary to previous reports, that this mutation exerts dominant-negative 
effects on heterologously expressed I BKsB. Our findings have several conceptual and clinical 
implications. 
Phenotypic Heterogeneity in a LQTS Founder Population 
 The concept that some patients might have LQTS and also a normal QT interval (phenotypic 
heterogeneity) was originally proposed in 1980P P(65). Support for this hypothesis emerged with the 
observation that within the International LQTS RegistryP P(7) approximately 5-6% of family members 
with a QTc < 440 ms suffered cardiac eventsP P(66). In 1992, Vincent et al.P P(67) reported that in 3 
LQTS families linked to chromosome 11 there was overlap in QTc duration in the range of 440-460 
ms between MCs and non-carriers, and that 6% of carriers had a QTc<440 ms. The relationship 
between clinical heterogeneity and the phenomenon of low penetrance was demonstrated by Priori 
et al.P P(68) in 1999 by showing that asymptomatic MCs with normal QT intervals can be identified in 
LQTS families. 
The observation of incomplete penetrance in LQTS impacts the estimation of disease 
prevalence, fosters the notion that a reduced “repolarization reserve”P P(69) might create a substrate 
predisposing to drug-induced Torsades-de-Pointes, and defines a clinically important subset of 
LQTS patients as “silent mutation carriers” that have a latent form of the syndrome. Explaining 
incomplete penetrance in LQTS is a great challenge that will require new clinical resources and 
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insights into disease behavior. We believe that the South African LQTS founder population is such 
a resource and has great potential for addressing important unanswered questions about this disease. 
 Our present data further illustrate phenotypic heterogeneity in LQTS within a large 
population of related LQTS individuals carrying the same primary mutation. Given the expectation 
that all individuals carrying KCNQ1-A341V should have similar reductions in IBKs B, our findings 
point to the existence within this South African population of additional genetic or environmental 
influences affecting duration of the QT interval and the probability of cardiac events. Common 
variants in cardiac ion channel genes similar to or including those recently described by Pfeufer et 
al.P P(70) are excellent candidate modifiers. In this regard, we have demonstrated in our IT-A1116V 
family, that a very common KCNH2 polymorphism (K897T) can exaggerate loss of repolarizing 
current produced by a LQTS mutation and unmask a severe clinical phenotypeP P(71). Equally 
plausible are modifier genes having no obvious link to myocyte electrophysiology. 
Heart Rate as a Risk Factor in LQTS 
 The repolarizing current I BKs Bactivates during increased heart rate and is essential for QT 
interval adaptation during tachycardia. Without this adaptive response the progressive reduction in 
the RR interval could lead to ventricular activation during the vulnerable period of the T wave P P(72) 
increasing the probability of ventricular fibrillation. This helps to explain why 79% of the lethal 
arrhythmic episodes in LQT1 patients, with mutations impairing IBKs B, occur during exerciseP P(12). 
This is in striking contrast to the observation that most lethal episodes for LQT2 and LQT3 patients 
occur during startle reactions and at rest or sleep, respectively (12). 
 Adrenergic activation, as well as fast heart rates (even without adrenergic activation), lead to 
accumulation of I BKs PB P(73). In LQT1 patients, IBKs Baccumulation is impaired caused by reduced function 
of channels containing a mutant subunit and may contribute to reduced adaptation of action 
potential duration during increased heart rate, the well-known “failure to shorten” the QT interval 
on exercise characteristic of LQT1. This phenomenon also facilitates the occurrence of electrical 
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alternans, which often manifests on the surface ECG as T wave alternans, a phenomenon described 
first in an LQT1 patient under emotional stressP P(74) and recognized as a marker of cardiac electrical 
instability often preceding onset of Torsades-de-Pointes. 
 The critical role of IBKs B in QT adaptation led us to explore if the propensity to develop cardiac 
events in the SA-A341V population was related to heart rate. We found that while symptomatic 
MCs had values almost identical to those of the non-carriers, the asymptomatic carriers had a 
significantly lower heart rate at rest. Indeed, a resting heart rate <73 bpm significantly lowered the 
probability of having arrhythmic events. Thus, a lower heart rate - even with the caution necessary 
when dealing with relatively small differences- appears to be a protective factor for patients with 
mutations affecting IBKs. BThis novel finding may partially explain the high efficacy of ß-blocker 
therapy for LQT1 patients. Indeed, our two recent studies showed that in 157P P(75) and in 187 (76) 
LQT1 patients the long term combined incidence of cardiac arrest and sudden death was only 1.2% 
and 1.1%, respectively. Thus, it appears that ß-blockers are effective in LQT1 patients because they 
act not only on the triggersP P(12) but also on the substrate by modifying heart rate. 
 On the other hand, while patients with a resting heart rate ≥73 bpm were all at higher risk for 
cardiac events (OR=4.22, 95% CI 1.13-15.81; p=0.033), within the patients with a QTc<500 ms 
there was a linear correlation between risk and heart rate level. This is practically important because 
it suggests that when the substrate is weaker the arrhythmogenic role of faster rate becomes 
predominant whereas it is somewhat less important in the presence of a major arrhythmogenic 
substrate (QTc≥500 ms). This finding, to be accepted within the caution appropriate for 
extrapolations from a single ECG tracing, contributes to the novel concept, originated by this study, 
that heart rate plays a significant modulating role on the risk for cardiac events and that this 
arrhythmogenic role is accentuated in the presence of a moderate - but not excessive - QT 
prolongation. 
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Lower Baroreflex sensitivity correlates with reduced arrhythmia risk  
 In the present study we also tested the hypothesis (77) that the different clinical severity 
observed among family members carrying the same LQT1 mutation might be due to inborn or 
acquired variations in the autonomic control of heart rate. To reduce the possibility of chance 
observations we studied members of a founder population all carrying the same mutation (KCNQ1-
A341V), focused on the age group in which autonomic responses were not influenced by age (2nd 
and 3rd age quartiles), and, given the potentially confounding role of BB, performed the study both 
on and off treatment.  
Our hypothesis was that a reduced or relatively low BRS would have been associated with 
greater arrhythmic risk. This was the pattern that predicts increased arrhythmic and mortality risk 
after a myocardial infarction (14,78-80). Contrary to our expectations, we actually found that lower 
BRS values were associated with reduced risk. There is, however, a plausible biological explanation 
for this finding. At variance with patients affected by ischemic heart disease who are at risk when 
there is insufficient vagal activity to antagonize the arrhythmogenic sympathetic activity (81), 
LQT1 subjects are at greatest risk for arrhythmias whenever heart rate changes too rapidly. When 
heart rate increases quickly, reduced IKs prevents the necessary QT adaptation (QT shortening) and 
a new ventricular depolarization may encroach the vulnerable phase of the T wave (72), thus 
initiating ventricular tachycardia or fibrillation. When heart rate decreases quickly, the sudden RR 
lengthening may increase the amplitude of early after-depolarizations and initiate Torsades-de-
Pointes through triggered activity 
Indeed, those MCs who have a BRS value in the lower tertile (<12 ms/mmHg), had a 
markedly reduced risk of being symptomatic with an odds ratio of 0.13. In addition, when the 
analysis was restricted to the patients with a less severe arrhythmogenic substrate (QTc ≤500 ms) 
the probability of being symptomatic was dependent on the level of BRS. In addition to the fact that 
none of the MCs in the lower tertile for BRS had symptoms, it is worth noting (Fig. 15) that the 
only two asymptomatic patients with a BRS > 12 ms/mmHg also had borderline QTc prolongation 
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(445 and 454 ms). This suggests that within these South African families when the substrate is not 
overwhelmingly arrhythmogenic (QTc ≤500 ms) there are two distinct patterns observed in 
asymptomatic MCs: relatively low BRS even with a prolonged QTc (490-500 ms) or BRS > 12 
ms/mmHg and a near normal QTc. The reduced arrhythmia risk associated with lower BRS values 
persisted in the absence of BB even despite the small sample size. 
Taken altogether, these data provide evidence that the individual autonomic make-up, as 
represented by BRS, effectively contributes to modulate arrhythmic risk in patients with the 
KCNQ1-A341V mutation. Indeed, in this population  a “blunted” autonomic response, as revealed 
by relatively low BRS, is a protective factor and may possibly hold true in other LQT1 subjects. 
Clinical Severity in SA-A341V 
 In studying this founder population, we made the serendipitous finding that KCNQ1-A341V 
is associated with a very high incidence of cardiac events. Previously, the only suggestion that 
different mutations could carry a different risk for cardiac events was limited to their location in the 
predicted topology of the gene product, and most of the interest focused on whether or not the 
mutations were located within or outside the pore region. Donger et al. P P(82) suggested that KCNQ1 
C-terminal mutations are associated with a forme fruste of LQTS and Moss et al.P P(57) provided 
evidence for a more malignant clinical course associated with KCNH2 mutations in the pore region. 
Subsequently, Zareba et al.P P(83) reported that among LQT1 patients no differences in the risk for 
cardiac events were observed between those with transmembrane mutations and those with C-
terminal mutations. By contrast, Shimizu et al. P P(84) found that LQT1 patients with transmembrane 
mutations were at higher risk for cardiac events. 
 In the present study, we found that KCNQ1-A341V is associated with an unusually severe 
clinical phenotype in the South African population. This conclusion is supported by multiple lines 
of evidence. There is a striking, and highly significant, difference in the percentage of symptomatic 
patients and in Kaplan-Meier survival curves between SA-A341V patients and LQT1 database 
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patients with a diversity of mutations. Furthermore, when the analysis was limited to the more 
homogeneous group of females with a QTc≥500 ms, the large difference in the probability of 
experiencing a cardiac event was still observed. Finally and importantly, cardiac mortality is 
particularly high in these patients as 23 of 166 (14%) died suddenly. 
Given the importance of this finding, we compared our SA-A341V population also to the 
one reported by Zareba et alP P(19) even though it included only 112 patients from 10 families. This 
was done because Zareba’s population had an average QTc very similar to that of the SA-A341V 
patients (490±43 vs 487±45 ms). The Kaplan-Meier curves remained significantly different 
(p<0.01) as significant were the difference of patients with a first event by age 15 (55% vs 80%, 
p<0.001) and the difference in mortality (2% vs 14%, p<0.001). This conclusively demonstrates the 
unusual clinical severity associated with A341V. Our data also confirm the major prognostic 
importance of a QTc≥500 ms, but in a more genetically uniform population compared to previous 
studiesP P(30,85). 
Dominant Suppression of IBKs B by KCNQ1-A341V 
Previous studies examining the functional consequences of KCNQ1 mutations associated 
with LQTS have revealed a spectrum of channel dysfunction. Consistent with the autosomal 
dominant inheritance of Romano-Ward syndrome, many KCNQ1 mutations exert dominant-
negative effects on the WT channel in heterologous expression systems, whereas mutations 
associated with the Jervell and Lange-Nielsen syndrome are typically pure loss-of-function alleles. 
Prior characterization of KCNQ1-A341V in oocytesP P(44-46) or COS7 cellsP P(47) demonstrated little 
or no dominant activity of this mutation suggesting that it may be associated with a milder form of 
the disease. However, our survey of the phenotype associated with this allele indicates that it 
confers a more severe clinical picture (Figs. 17-20). We reassessed the functional properties of this 
mutation by using a mammalian cell system that insures co-expression of both WT and mutant 
channels with the KCNE1 accessory subunit. This system avoids the potential confounding 
influence of endogenous KCNQ1 and KCNE channel subunits that exist in Xenopus oocytes and the 
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uncertainties associated with transient transfection of multiple separate plasmids in COS7 cellsP P(47). 
Our findings indicate that KCNQ1-A341V exerts a dominant-negative effect on I BKs Band therefore is 
not a pure loss-of-function mutation. This is more consistent with an allele associated with a severe 
clinical phenotype. 
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CONCLUSIONS AND CLINICAL IMPLICATIONS 
 
The present data amplify the evidence for phenotypic heterogeneity in LQTS and indicate 
that even within populations sharing an identical mutation due to a founder effect there is a wide 
spectrum of clinical manifestations.  
Our findings also indicate that risk stratification for LQTS patients must be more 
individually tailored and may have to take into account the specific mutation (i.e. KCNQ1-A341V 
was associated with a more severe phenotype compared to other LQT1 mutations) and probably 
additional clinical (i.e. HR, BRS) and genetic variables (i.e. KCNH2-K897T and other SNPs) 
capable of influence/predict the clinical phenotype of LQTS patients.  
The study of the Italian LQT2 family gave the first clinical, genetic and electrophysiological 
evidence indicating that a very common non-synonymous SNP (30% carrier frequency among 
Caucasians) can act as a genetic modifier of the clinical expression of a LQTS mutation having low 
penetrance. This further validates the concept of genetic modification of LQTS by a common 
variant and carries important practical implications, as similar mechanism may contribute to the risk 
for sudden cardiac death in more prevalent diseases.  
        The study of the South African founder LQT1 population allowed us to identify heart rate and 
BRS, two autonomic markers, as novel risk factors. It is also evident that this South African LQTS 
population represents a useful human disease model for the identification and study of modifier 
genes. 
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